# A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06741644/  
OnCo record `nct06741644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pemetrexed, Carboplatin, Etoposide, Oxaliplatin, Capecitabine and Docetaxel in advanced solid tumours, run by CStone Pharmaceuticals, now recruiting.

## Summary

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06741644 by CStone Pharmaceuticals, with 800 participants planned, started 2025-02-24 and due to reach its primary completion in 2027-01. Interventions recorded: CS2009, Pemetrexed, Carboplatin, Paclitaxel, Etoposide and Nab-paclitaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06741644
- Phase: 1/2
- Setting: A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors
- Sponsor: CStone Pharmaceuticals
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT06741644: https://clinicaltrials.gov/study/NCT06741644

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Etoposide](https://onco.cc/drugs/etoposide/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [CStone Pharmaceuticals](https://onco.cc/companies/cstone/)

---
JSON: https://onco.cc/api/v1/entities/nct06741644.json